SCHEMBL1763076

SCHEMBL1763076

O=CN1C(c2ccccc2)CCC1c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.42
CHRNB4 P30926 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA7 P36544 1/20 0.42
CHRNA4 P43681 1/20 0.42
KMT2A Q03164 3/20 0.40
ALDH1A1 P00352 2/20 0.40
RAB9A P51151 1/20 0.40
RIPK1 Q13546 4/20 0.40
MEN1 O00255 2/20 0.39
POLB P06746 1/20 0.39
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C19 P33261 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1763911 1.00 CHRNB2 (0.42) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL1763075 1.00 CHRNB2 (0.42) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL12604447 0.87 CHRNB2 (0.37) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL12593440 0.75 CHRNB2 (0.44) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL28527413 0.75 RIPK1 (0.45) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL17443221 0.75 ROCK2 (0.41) CHRNA7ALDH1A1RIPK1MAPTCYP2C19
SCHEMBL442161 0.75 CHRNB2 (0.47) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL13330544 0.72 CHRNB2 (0.55) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL8846952 0.71 CHRNB2 (0.49) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4
SCHEMBL28612102 0.71 KMT2A (0.38) CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759541-B2 Chiral acyclic diaminocarbene ligands, precursors therefore and their use in organic synthesis reactions THADANI AVINASH N (CA) 2014-06-24 US disclosed
US-20110118475-A1 CHIRAL ACYCLIC DIAMINOCARBENE LIGANDS, PRECURSORS THEREFORE AND THEIR USE IN ORGANIC SYNTHESIS REACTIONS THADANI AVINASH N 2011-05-19 US disclosed
WO-2010003226-A1 CHIRAL ACYCLIC DIAMINOCARBENE LIGANDS, PRECURSORS THEREFORE AND THEIR USE IN ORGANIC SYNTHESIS REACTIONS THADANI AVINASH N (CA) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118475-A1 CHIRAL ACYCLIC DIAMINOCARBENE LIGANDS, PRECURSORS THEREFORE AND THEIR USE IN ORGANIC SYNTHESIS REACTIONS AOC1, ODC1, AMD1 CHRNB2 1049/4885CHRNB4 1529/4885CHRNA3 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.